Investment Thesis
Annovis Bio is a pre-revenue pharmaceutical company with severe cash burn of $25.6M annually, consuming its cash reserves at an unsustainable rate. With $19.5M in cash and negative $25.6M operating cash flow, the company has less than one year of cash runway remaining. The absence of any revenue generation combined with massive operating losses and deteriorating financial position presents existential risks.
Strengths
- Strong liquidity position with $19.5M in cash relative to $21.1M total assets
- Minimal debt burden with 0.00x debt-to-equity ratio reducing financial leverage risk
- Current ratio of 2.15x indicates ability to meet short-term obligations
Risks
- Zero revenue with no path to profitability visible in near term
- Negative operating cash flow of $25.6M annually indicating unsustainable burn rate with <1 year cash runway
- Pre-clinical stage pharmaceutical company dependent on successful drug development, regulatory approval, and commercialization
- Severe negative profitability metrics: -171.2% ROE, -136.9% ROA, -28.9M net loss
- No insider buying activity in last 90 days suggesting lack of management confidence
Key Metrics to Watch
- Quarterly operating cash flow trend and remaining cash balance
- Clinical trial progress and regulatory milestones for pipeline assets
- Burn rate sustainability and capital raise requirements
Financial Metrics
Revenue
0.0
Net Income
-28.9M
EPS (Diluted)
$-1.40
Free Cash Flow
-25.6M
Total Assets
21.1M
Cash
19.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-171.2%
ROA
-136.9%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
2.15x
Quick Ratio
2.15x
Debt/Equity
0.00x
Debt/Assets
20.1%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-19T22:28:11.263810 |
Data as of: 2025-12-31 |
Powered by Claude AI